Sarah Cannon Research Institute Investigator Authors Ten Studies for Presentation at San Antonio Breast Cancer Symposium - Hyatt Hotels (NYSE:H)

NASHVILLE, Tenn.--(BUSINESS WIRE)--

Denise A. Yardley, M.D., senior investigator, breast cancer research for Sarah Cannon Research Institute (SCRI) serves as primary or co-author of ten breast cancer clinical trial abstracts that have been accepted for presentation during the 34^th Annual San Antonio Breast Cancer Symposium (SABCS), which takes place Dec. 6-10 in San Antonio, Texas.

“It's exciting to share so many of our abstracts with our scientific colleagues at the San Antonio Breast Cancer Symposium,” SCRI Chief Medical Officer and Executive Director, Drug Development Howard A. Burris III, M.D. said. “The research findings are compelling and show innovations in all phases of breast cancer.”

Dr. Yardley will present three of the studies, for which she is principal investigator and lead author, at the meeting. Two of the three will be presented in oral poster sessions and one in an ongoing trials session. Details are as follows:

Presentation Title:		Presentation Time:
Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple- Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial		Poster session 3 12/8/11, 5:15-7PM Exhibit Halls A & B
Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial		Poster session 5 12/9/11, 5-7PM Exhibit Halls A & B
Eribulin in Women with Locally Advanced Breast Cancer Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy: A Sarah Cannon Research Institute Phase II Trial		Ongoing trials session 2 12/8/11, 5:15 -7PM Exhibit Hall B

Results of seven additional studies will be presented at the conference, for which Dr. Yardley serves as primary or co-author. These are as follows:

Presentation Title:		Presentation Time:
Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study		Poster discussion 1 12/7/11, 5-7PM Ballroom A First author: Dr. Yardley
Phase II Study Evaluating Lapatinib (L) in Combination with Albumin Bound Paclitaxel (ab-Pac) in Women Who Have Received 0-1 Chemotherapy Regimen for HER2 Overexpressing (HER2+) Metastatic Breast Cancer (MBC)		Poster session 1 12/7/11, 5-7PM Exhibit Halls A & B First author: Dr. Yardley
Effect of Denosumab Treatment for Patients with Breast Cancer and Bone Metastases: Results from the Open-Label Extension Treatment Phase		Poster session 3 12/8/11, 5:15-7PM Exhibit Halls A & B Co-author: Dr. Yardley
Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA)		Poster session 2 12/8/11, 7-9AM Exhibit Halls A & B Co-author: Dr. Yardley
Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2-Positive Metastatic Breast Cancer from the registHER Observational Study		Poster session 1 12/7/11, 5-7PM Exhibit Halls A & B Co-author: Dr. Yardley
Discordance between Central and Local Laboratory HER2 Testing from a Large HER2-Negative Population in VIRGO, a Metastatic Breast Cancer Registry		Poster session 1 12/7/11, 5-7PM Exhibit Halls A & B Co-author: Dr. Yardley
Z-ACT1: Zometa Combined with Standard Therapy in Patients with Metastatic Breast Cancer Further Decreases the Proportion of Patients with CTC Counts of 5 or above		Poster session 1 12/7/11, 5-7PM Exhibit Halls A & B Co-author: Dr. Yardley

About SABCS

The objective of the SABCS is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease, to an international audience of academic and private physicians and researchers. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.

About SCRI

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit www.sarahcannonresearch.com.

Sarah Cannon Research Institute
Anna Walker, 615-329-7216
Anna.Walker@scresearch.net

Market News and Data brought to you by Benzinga APIs